Ac­tive Biotech shares crater af­ter Teva's MS drug laquin­i­mod flops (again); FDA ap­proves Foun­da­tion Med­i­cine's ge­nom­ic tu­mor di­ag­nos­tic test

We al­ready knew from a Phase III read­out last spring that Te­va’s big mul­ti­ple scle­ro­sis drug hope laquin­i­mod didn’t work in treat­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.